Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) EPS (Basic) (2019 - 2025)

Benitec Biopharma has reported EPS (Basic) over the past 7 years, most recently at -$0.26 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.26 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was -$0.93 (down 19.23% YoY), and the annual figure for FY2025 was -$1.05, up 13.93%.
  • EPS (Basic) reached -$0.26 in Q4 2025 per BNTC's latest filing, down from -$0.22 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.11 in Q2 2024 and bottomed at -$36.27 in Q2 2022.
  • Median EPS (Basic) over the past 5 years was -$0.5 (2021), compared with a mean of -$3.15.
  • The largest annual shift saw EPS (Basic) tumbled 11990.0% in 2022 before it skyrocketed 95.85% in 2024.
  • Over 5 years, EPS (Basic) stood at -$0.59 in 2021, then plummeted by 466.1% to -$3.34 in 2022, then grew by 20.96% to -$2.64 in 2023, then skyrocketed by 90.15% to -$0.26 in 2024, then changed by 0.0% to -$0.26 in 2025.
  • Business Quant data shows EPS (Basic) for BNTC at -$0.26 in Q4 2025, -$0.22 in Q3 2025, and -$0.21 in Q2 2025.